Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peking Univ. FGFR4 compound 10v: sourced facts only. name: "Representative compound 10v exhibited potent FGFR4 inhibition (IC50 = 1.2 nM) and a high selectivity among the tested kinases." [PMID:41187564]; target: "Representative compound 10v exhibited potent FGFR4 inhibition (IC50 = 1.2 nM) and a high selectivity among the tested kinases." [PMID:41187564]; developer: "State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China." [PMID:41187564]; modality: "Herein, we report a novel series of 7-azaindole-based compounds as potential type-II covalent inhibitors against FGFR4 kinase." [PMID:41187564]; stage: "Moreover, compound 10v exhibited significant in vivo antitumor activity in a HuH-7 mouse xenograft model." [PMID:41187564]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peking Univ. FGFR4 compound 10v.